Marco Meglio, Assistant Managing Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at [email protected]
The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts. [WATCH TIME: 3 minutes]
After demonstrating a significant effect in reducing the frequency of drop seizures, fenfluramine aims to build on its previous indication in rare epileptic disorders, as it is currently approved to treat Dravet syndrome.
The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed his recently published research on the costs of developing treatments for Alzheimer disease.
Phase 3 study represented the highest research and development costs for Alzheimer disease treatments, with more than $24.1 billion incurred.
In addition to a well-tolerated safety profile, investigators observed a dose proportional increase in plasma pharmacodynamics in the MONARCH study cohort of 21 children and adolescents.
Annualized attack rate was reduced to 0.08 attacks per year after the first administration of inebilizumab, similar to those who were not previously exposed to rituximab.
As more organizations begin to adopt palliative care practices for patients with Parkinson disease, some may turn to the implemented plans of Cleveland Clinic as an example to follow.
Positive phase 2 data resulted in a breakthrough therapy designation for donanemab, (Eli Lilly), prompting a biologics license application submission for the agent.
The Bruton tyrosine kinase inhibitor has been evaluated in 2 phase 3 trials, GEMINI 1 and GEMINI 2 (NCT04410978; NCT04410991), in patients with relapsing-remitting and relapsing secondary progressive MS.
In a NeurologyLive® Insights series, experts in the diagnosis and treatment of Dravet syndrome discussed the management of the disease and the utilization of approved treatments to improve outcomes in patients.
The director of the Comprehensive Epilepsy Center at NYU Langone discussed the large-scale impact heart rate variability has on preventing SUDEP and the unanswered questions that remain.
In cognitively impaired vs unimpaired patients, investigators found functional connectivity decreases in DMNa and DMNp and increases in the right and left frontoparietal networks.
A total of 77 patients randomized to either ATH-1017 or placebo will be evaluated for improvements in cognition, global, and functional assessments across a 26-week treatment period.
The risk of dementia was substantial and front-loaded following stroke, with the 1-year prevalence similar to the estimate for dementia at any time point. The findings indicate a need for greater engagement between stroke and dementia care.
Reduced low-frequency power measured at rest was independently associated with an elevated SUDEP risk, presumably through arrhythmogenic mechanisms.
The optimal range of HbA1c between 6.8% and 7.0% at admission was estimated to have the minimum risk for composite vascular events and stroke recurrence, with notably different levels according to stroke subtype.
Despite not being significantly superior to placebo on agitation and aggression, lithium showed a greater reduction in those with high Young Mania Rating Scale scores.
The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.
Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising results from ECTRIMS, which found no evidence of wearing off with ocrelizumab (Ocrevus; Genentech).
Patients with REM sleep percentage less than 15% were associated with poorer horizontal optokinetic nystagmus grades and more severe illness.
The findings, which suggest that high plasma GFAP levels are parallel with AD and are markers of tau pathology, hold important implications in facilitating the detection of Alzheimer disease, particularly in the preclinical stage.
In addition to changes in CCL2 levels, anxiety and health-related quality of life were both significantly increased in both the valproate and add-on levetiracetam groups.
The director of the Comprehensive Epilepsy Center at NYU Langone discussed his recently published research, which identified a novel biomarker for sudden unexpected death in epilepsy.
The long-term benefits observed were due to maintenance of the early effect, rather than any additional benefit accrued after 90 days of the initial event, with no evidence either of rebound or loss of benefit.
Over 26 weeks of treatment, masupirdine demonstrated a sustained and durable effect on outcomes such as cognition and dementia-related psychosis.
Beginning enrollment in 2022, the NAUTILUS pivotal study will be the first in the United States to evaluate brain-responsive neuromodulation in patients with idiopathic generalized epilepsy.
Even after adjusting to traditional stroke risk factors, the associations between clonal hematopoiesis and all stroke types, ischemic stroke, and hemorrhagic stroke remained significant.
Despite the cohort only consisting of 3 patients with Alzheimer disease, autologous cellular therapy data highlighted the potential of the treatment’s results on cognitive assessments such as Montreal Cognitive Assessment.
Those who received an infusion of ABBV-951, consisting of foslevodopa/foscarbidopa, showed statistically significant increases in hours of ON time without troublesome dyskinesia compared with oral levodopa/carbidopa.
Twelve months after subthalamic deep brain stimulation, patients with and without RBD had MDS-UPDRS IV score decrease, MDS-UPDRS III MedOff decrease, and total LEDD decrease, with no between group difference.
